Hims(US:HIMS) ZACKS·2026-02-12 16:01Core Insights - Hims & Hers Health, Inc. (HIMS) is transforming healthcare delivery through a consumer-first digital platform focused on personalized, at-home care, with nearly 2.5 million subscribers as of Q3 2025 [1][7] Company Developments - The company has launched new offerings in men's health, including a testosterone category and compounded therapies, as well as a menopause specialty for women, both featuring personalized treatment plans [2][7] - Hims & Hers introduced Labs, a whole-body diagnostic service that combines biomarker testing with doctor-developed action plans, moving towards a preventive healthcare model [3][7] Market Performance - Hims & Hers shares have decreased by 71.8% over the past year, underperforming the industry average decline of 40.2% [6] - The forward 12-month price-to-sales ratio for HIMS is 1.4X, significantly lower than the industry average of 3.5X and its three-year median of 2.6X, indicating potential undervaluation [8] Earnings Estimates - The Zacks Consensus Estimate for HIMS' earnings per share in 2025 suggests a 77.8% improvement from 2024, with estimates ranging from a low of $0.39 to a high of $0.57 [9][10]